MABWELL BIOTECH
Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.
MABWELL BIOTECH
Industry:
Biopharma Biotechnology Life Science
Founded:
2017-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.mabwell.com
Total Employee:
11+
Status:
Active
Total Funding:
278.5 M USD
Similar Organizations
5Lmeet
5Lmeet is a Chinese co-working space company.
AVATAMED
Biotechnology, Biopharmaceutical
Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
BiondVax
BiondVax is an innovative biopharmaceutical company.
Chime Biologics
Chime Biologics is a biopharmaceutical development and manufacturing company.
CMAB BioPharm
CMAB BioPharm is a Biopharmaceutical Service Firm.
EOC Pharma Group
EOC Pharma is an integrated biopharmaceutical company.
EpimAb Biotherapeutics
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company.
Excell Biology
Excell Biology is a supplier of raw materials to the biopharmaceutical and precision medicine industries.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Future High-tech
Future High-tech is a shanghai based Industrial & Manufacturing company.
GenomiCare Biotechnology
GenomiCare Biotechnology is a Chinese precision cancer medicine service company
Great Bay Bio
Great Bay Bio is a high-tech company developing blue ocean biopharmaceuticals with a digital CMC platform.
Immunophage Biotech
Immunophage Biotech is a Nanjing-based pharmaceutic company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Majecules
Research as a service, Saas, Education
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
OPM Biosciences
Biotech company based in Shanghai.
Pulse language (Maizhiyu)
Pulse language is an Internet Chinese medicine intelligent equipment company
Samsung Bioepis
Samsung Bioepis is a biopharmaceutical company.
Shandong Sinobioway
Sinobioway Bio-medicine Co is a research-driven biopharmaceutical company.
Suhua
Suhua is an innovative synthetic biotechnology skin care brand.
Swixx Biopharma
Swixx Biopharma fully represents biopharma companies in the CEE.
VivaVision Biotech
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Yudao Bio
Yudo Bio is a provider of biopharmaceutical products
ZSHK Laboratories
ZSHK Lab is a company located in Wan Chai, Hong Kong Island, Hong Kong.
Current Employees Featured
Founder
Investors List
Sincere Capital
Sincere Capital investment in Series A - Mabwell Biotech
Founder H Fund
Founder H Fund investment in Series A - Mabwell Biotech
Shiyu Capital
Shiyu Capital investment in Series A - Mabwell Biotech
Haitong Leading Capital Management
Haitong Leading Capital Management investment in Series A - Mabwell Biotech
Oriental Fortune Capital
Oriental Fortune Capital investment in Series A - Mabwell Biotech
Loyal Valley Capital
Loyal Valley Capital investment in Series A - Mabwell Biotech
Huajin Capital
Huajin Capital investment in Series A - Mabwell Biotech
Huarong Rongde Asset Management
Huarong Rongde Asset Management investment in Series A - Mabwell Biotech
Winfast Holding
Winfast Holding investment in Series A - Mabwell Biotech
Official Site Inspections
http://www.mabwell.com
- Host name: 47.101.141.235
- IP address: 47.101.141.235
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Mabwell Biotech"
Mabwell - Explore Life, Benefit Health
Mabwell is an innovation-driven biopharmaceutical company with an entire industry chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and …See details»
迈威生物 - 探索生命，惠及健康
迈威生物是一家全产业链布局的创新型生物制药公司，始终秉承“让创新从梦想变成现实”的愿景，践行“探索生命，惠及健康”的使命，通过源头创新，为患者提供疗效更好、可及性更强的生物创新药，满足全球未被满足的临床需求。See details»
Mabwell Biotech - Crunchbase Company Profile & Funding
Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly …See details»
Capabilities - mabwell.com
Mabwell is an innovation-driven biopharmaceutical company with an entire industry chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global …See details»
Mabwell (Shanghai) Bioscience Co., Ltd. - Drug pipelines ... - Patsnap
Nov 1, 2024 · Mabwell Biotech is a biopharmaceutical company headquartered in Shanghai's Zhangjiang Hi-Tech Park. The company was founded in 2017 and has since acquired and …See details»
Mabwell Therapeutics, Inc.
Jan 5, 2023 · We are striving to improve the lives of people with rare, debilitating diseases by leveraging the promise of science into novel antibody therapeutics. Following rigorous research and development guidelines, we are advancing …See details»
Mabwell, a Model Case of China’s Booming Biopharma …
May 27, 2021 · Mabwell, a values-based, R&D-driven biopharmaceutical company with more than 10 biologics pipelines focuses its efforts on five therapeutic areas: immunology, oncology, metabolic diseases,...See details»
Mabwell Presented IDDC™ Platform Technology and …
Mar 21, 2024 · Mabwell has independently developed IDDC™ technology and novel payload Mtoxin™. The study results show: 1. DARfinity™ produces site-specific conjugated drugs with DAR 4 as the main component (DAR...See details»
Press Releases | Mabwell Therapeutics, Inc.
Feb 5, 2021 · Mabwell Therapeutics, Inc. is a biotechnology company focusing on the discovery and development of antibody and protein-based drugs in multiple therapeutic areas including …See details»
Mabwell to Present the Clinical Data of 9MW2821 in Cervical …
SHANGHAI, March 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present the …See details»
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple …
SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical …See details»
Mabwell's 9MW2821 gains FDA fast track for breast cancer
Jul 15, 2024 · Developed using Mabwell’s ADC platform and automated hybridoma antibody molecular discovery platform, 9MW2821 is the first site-specific conjugated Nectin-4-targeting …See details»
News - mabwell.com
Mabwell is an innovation-driven biopharmaceutical company with an entire industry chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and …See details»
FDA clears clinical trial of Mabwell's IL-11 antibody therapy for...
Jun 16, 2023 · The U.S. Food and Drug Administration has given the green light for Mabwell Therapeutics to launch a clinical trial testing 9MW3811, its injectable treatment candidate for …See details»
Mabwell to Present the Clinical Data of 9MW2821 in Cervical …
Mar 8, 2024 · Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible …See details»
Mabwell Announces 9MW2821 Clinical Data and Latest Progress …
May 24, 2024 · 9MW2821 is the first site-specific conjugated novel Nectin-4-targeting ADC developed by Mabwell using ADC platform and automated high-throughput hybridoma …See details»
Mabwell Stages $547 Million IPO on STAR Board for Antibody …
Jan 20, 2022 · Mabwell (Shanghai) Bioscience completed a $547 million IPO on Shanghai's STAR Board. Established in 2017, Mabwell is a clinical-stage antibody developer with 15 …See details»
Mabwell Launched First Human Clinical Trial of Its Iron …
Mar 14, 2023 · Mabwell, a biopharmaceutical company, launched the first human clinical trial of its iron homeostasis-regulating macromolecular drug 9MW3011.See details»
Mabwell receives approval for trial of urothelial carcinoma drug
Aug 27, 2024 · US-based biopharmaceutical company Mabwell Therapeutics has received approval from China’s National Medical Products Administration (NMPA) to begin a Phase III …See details»
Mabwell Releases Preclinical Study Results of Multiple Innovative …
Apr 16, 2024 · Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible …See details»